SCHEMBL1043997

SCHEMBL1043997

O=C(O)c1ccc(OCCNC(=O)[C@@H]2Cc3ccccc3N2S(=O)(=O)c2ccc(-c3ccc(F)cc3)cc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MMP8 P22894 9/20 0.45
MMP3 P08254 6/20 0.45
ALDH1A1 P00352 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.40
PTGER3 P43115 1/20 0.40
MMP1 P03956 1/20 0.39
MMP9 P14780 1/20 0.39
MMP13 P45452 1/20 0.39
ADAM17 P78536 1/20 0.39
RORC P51449 1/20 0.39
BCL2L1 Q07817 1/20 0.39
MCL1 Q07820 1/20 0.39
USP2 O75604 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4840536 1.00 MMP8 (0.45) MMP8MMP3ALDH1A1NPSR1RAB9A
SCHEMBL4840519 0.99 MMP8 (0.44) MMP8MMP3ALDH1A1NPSR1RAB9A
SCHEMBL4840527 0.93 MMP8 (0.44) MMP8MMP3ALDH1A1NPSR1RAB9A
SCHEMBL4838417 0.92 MMP8 (0.44) MMP8MMP3ALDH1A1NPSR1RAB9A
SCHEMBL4833757 0.92 CA12 (0.42) MMP8MMP3ALDH1A1NPSR1RAB9A
SCHEMBL4833189 0.90 MMP8 (0.49) MMP8MMP3ALDH1A1NPSR1SMN1; SMN2
SCHEMBL4842689 0.90 MMP8 (0.39) MMP8MMP3ALDH1A1NPSR1PTGER3
SCHEMBL4845030 0.90 ALDH1A1 (0.40) MMP8MMP3ALDH1A1NPSR1RAB9A
SCHEMBL4844870 0.90 MAPT (0.42) MMP8MMP3ALDH1A1NPSR1MMP1
SCHEMBL4833917 0.89 MMP8 (0.43) MMP8MMP3ALDH1A1NPSR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2268270-A2 IMPROVED FORMULATIONS FOR POORLY PERMEABLE ACTIVE PHARMACEUTICAL INGREDIENTS Abbott Products GmbH (DE) 2011-01-05 EP claimed
WO-2009130204-A2 IMPROVED FORMULATIONS FOR POORLY PERMEABLE ACTIVE PHARMACEUTICAL INGREDIENTS SOLVAY PHARMACEUTICALS GMBH (DE) 2009-10-29 WO claimed
US-20090263479-A1 FORMULATIONS FOR POORLY PERMEABLE ACTIVE PHARMACEUTICAL INGREDIENTS SOLVAY PHAMACEUTICALS GMBH 2009-10-22 US claimed
US-20090263479-A1 FORMULATIONS FOR POORLY PERMEABLE ACTIVE PHARMACEUTICAL INGREDIENTS SOLVAY PHAMACEUTICALS GMBH 2009-10-22 US disclosed
US-7465811-B2 Indoline compounds LABORATOIRES FOURNIER S.A. (FR) 2008-12-16 US disclosed
US-20080119465-A1 Novel Indoline Compounds LABORATORIES FOURNIER S.A. (FR) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119465-A1 Novel Indoline Compounds GPR119, INSR, IRS1 MMP8 3968/4885MMP3 3739/4885ALDH1A1 1819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.